Strategy 101
Mark, you made an astute comment earlier that I believe hit the nail on the head, and I wanted to add to it:
It's clear on this thread, if it weren't already obvious, that in order for everyone to back the CAA, the CAA would need to change. Change the leader, change the policy, change the strategy - those who've left won't return without that.
A Strategic Fork in the Road for the CAA
The time is nigh approaching when advocating/research needs for depressed/sedentary patients will become irrelevant to - and
blatantly incompatible - with the advocating/research needs of the neuro-immune disease ME/CFS. I say blatantly, because ME/CFS patients have understood this inherent and obscene contradiction all along. What WILL be a politically important tipping point however, will be when
powerbrokers like Lipkin and Collins openly define ME/CFS as a retrovirally-associated neuro-immune entity, discrete from psychogenic and idiopathic CFS. Timing is everything, and I am inclined to think that when THAT public acknowledgement of this dichotomy happens, the patient community - and indeed government and research community - must DEMAND a crystal clear redefined statement of Mission from of the CAA.
WHICH strategic direction does the CAA intend to take?
Because in order to achieve credibility, I believe the CAA WILL need to choose. By not choosing for the last 20 years (as WillowJ intimated in an earlier post), the CAA has sowed confusion (and slowed our deliverance from this hellhole of ME/CFS) by advocating CBT/GET-as-treatment, without
meticulously and 100%-of-the-time, separating the potential benefits for depressed patients, from the dire dangers of these modalities for ME/CFS patients. And even if the CAA had had a squeaky clean approach to these issues, the omnipresent potential for media confusion, and distortion of facts by the psycholobby has pervaded and tainted progress. By the time Collins
et al openly acknowledge that ME/CFS is a discrete entity, the strategic illogic and indeed clinical danger of "having it all" in the world of "CFS" will have become abundantly and tragically clear.
- Will the CAA go for the 90% market share, and elect to represent psychogenic fatigue - and jettison XMRV/MLV neuro-immune ME/CFS?
- Will they jettison psychogenic fatigue, and aim to represent the recently high-profile interests of the XMRV/MLV neuro-immune ME/CFS community?
- Does it matter what they choose if more relevant organizations emerge? I don't say this to be spiteful. This is a VITAL question for the CAA board to address. Any reasonably competent Board faced with an organizational history of 20 years of trundling in low gear, trumped by a dark horse on a tight budget, in a couple of years, would HAVE to be asking tough questions and making courageous decisions in a bid to gain relevancy in this new environment. Particularly if they had turned away from earlier retroviral research.
The 3rd man: And what about the poor sods that have truly idiopathic fatigue, that don't have XMRV/MLV, that aren't depressed or sedentary, and that are cursed with the next generation of undiagnosed serious illness that happens to have "Chronic Fatigue" as one of its prominent clinical features? Who will speak, and guide research for them? It would be a colossal, indeed criminal act of deja-vu to lump them together with the all-fatigue-is-psychogenic aficionados, whether in an advocacy/research organization, or a government department.
A new Mission for the CAA: Bottom line, the CAA is approaching a massive fork in the road, and their Board and executives should be actively preparing for this imminent eventuality. Of course what mission the CAA chooses will not impact on the inevitable explosion and diversification of interest in ME/CFS. Just as there is a natural explosion of XMRV-related advocacy initiatives online already (and I submit this is a GOOD thing, better serving the mosaic of needs of this community, while also potentially building critical mass on issues we all agree on, such as accelerated clinical trials), I predict that we will see a proliferation of ME/CFS advocacy
organizations. Analyzing the start-ups doesn't really interest me, and for this reason when it comes to advocacy and education, I and many others like to lend psychic or tangible support to multiple initiatives. What WILL be interesting however will be the organizations with staying power. And it will be the organizations with relevance to the needs of ME/CFS patients, strategic clarity that is not muddied by a "We-serve-all-Chronic-Fatigue-patients" mandate, and scientific AND political credibility, that will survive the shakedown.
It would be naiive of the CAA to assume that their role as "inside voice" for the ME/CFS community will withstand the test of time and relevancy.
The leadership issue: And in the interim, what ABOUT that leadership issue? The CAA article blithely stated,
"CFS will not be solved by one person or one organization alone."
How is it then, that Annette Whittemore and the WPI have singlehandedly achieved more traction
internationally for ME/CFS socio-political issues AND science in 2-3 years than the CAA has achieved in America in 20? Painful though this may be for the CAA to acknowledge, it is VITAL. A brutally frank evaluation of this tipping point must happen, for the CAA to have any chance of relevancy or meaningful momentum in the next 2 decades - much less the next 2 years. If the earth-shattering events since October 8th, 2009 don't warrant a leadership, and indeed organization-wide strategic review, I don't know what does. It's strategy 101.
Let's call a spade a spade. "XMRV" didn't change everything. Annette Whittemore and the WPI did (with a canine nod also to George, Joe Derisi and his viro-chip). I'd add this isn't gratuitous wallowing-in-the-past. If the CAA doesn't face these facts head-on, and if the board shows no insight of how monumentally the CAA has been upstaged, they have no hope of
learning from their mistakes.
So what can individual patients DO?
With the increasingly limited energy/health I have, I am being forced to be ruthless about where I expend my energy. So user-friendly advocacy initiatives that provide ready-made letters for me to edit/email, and handy target lists of email addresses, are great as far as I'm concerned. The sick joke in this community is that our most experienced advocates ultimately become too ill to attend CFSAC, to form the next CAA, or to advocate VIGOROUSLY and consistently.
Finding political hotbuttons - and pushing them
As I see it, one of the fundamental impediments to us getting
SERIOUS research money is the facile perception that ME/CFS doesn't kill.
This is something that I CAN do something about, as out of necessity I've had to immerse myself in cardiac research to keep myself ticking. As I wrote in my submission to CFSAC (
http://www.hhs.gov/advcomcfs/meetings/presentations/pysiotherapistandoccupationaltherapist.pdf) I believe that vasculitis and endothelial dysfunction (dysfunction of the inner lining of our blood vessels, particularly the microcirculation) are a significant cause of cardiac and neurological issues in many ME/CFS patients.
On the flip side, the cardiology community is scratching their heads, trying to figure out why mostly women (but also men) with "Pain Syndromes" keep presenting to emergency departments with "Persistent Chest Pain" - but normal coronary arteries. And then within 5 years, some 40% of these patients have a major cardiovascular "event": stroke; myocardial infarction; cardiac hospitalization; or death.
Do you see a potential connection with us dying 25 years earlier from heart failure than the "normal" population? Our message boards are full with accounts of patients with nonspecific chest pain, who are being routinely laughed out of emerg departments and cardiologists' offices, because they test "normal" on
routine cardiac testing.
As it happens, the NHLBI has invested BIG money into understanding these women, called the WISE (or "Women's Ischaemic Syndrome Evaluation") study, and there is virtually a WISE industry funded by the NHLBI - many follow-up studies, of which I believe an XMRV/MLV and ME/CFS analysis should be one asap! I believe ME/CFS is the missing link in their understanding of what is called "Atypical Angina" in women and men. In other words, as I wrote in my submission to CFSAC, the NHLBI-funded researchers need to go back to their WISE cohorts with these "pain syndromes", evaluate them according to the Canadian ME/CFS Criteria, and test them for XMRV/MLV's, NK cell dysfunction, etc. I believe they will not only strengthen the outcomes for patients with endothelial dysfunction, opening up new avenues of more effective therapy, but also confirm the lethality of ME/CFS. And push that button for more FUNDING!
Coincidentally, Jamie Deckoff-Jones addressed endothelial/vascular dysfunction first in her list of pathophysiological groups that ME/CFS might be sorted into:
- "Vascular spasm (migraines, flashbacks, black outs, dysautonomia, microvascular angina, dysrhythmias, GI symptoms, Raynaud's)"
All this to say that while I look for opportunities to add my voice to issues that I believe would benefit from critical mass in advocacy, I am also quietly thinking about how to identify and push political hotbuttons, to help us leap-frog our progress more quickly forward. So when I'm able, I'm working on how to tackle this issue, and to build liaisons with the cardiology community. It's only one of many strategic hotbuttons, but it's one that I can do something about.
An Example of a Strategic Hotbutton: Proving that we're dying from ME/CFS
Proving that we're dying from Persistent Chest Pain and heart failure is one hotbutton that has been sorely neglected, but that could bring ME/CFS MUCH higher up on the research funding radar screen. Cardiologists are genuinely concerned that these women (and men) are dropping like flies. They WANT to improve these dismal outcomes! On the flip side, health administrators reel at the huge consumption of resources by these patients. Simply put, men and women with Persistent Chest Pain keep coming back to emergencies and to cardiologists over and over and over because we're not getting sensitive and specific enough diagnostics. And without a good diagnosis, the efficacy of cardiac therapy is crippled. Echocardiograms, stress tests, MRI's, CT's - the bread and butter of an emergency department/cardiologist's diagnostic toolkit - typically will MISS the diagnosis of vasculitis/endothelial dysfunction.
Suffice it to say, I believe that individuals can make a difference, particularly by working on the particular hotbuttons that they have potential influence over. The "
What to DO" question will be answered individually by different patients, depending on their health status, their background, and their aptitudes.
Focus actions that drive BREAKTHROUGH change
But I do believe it behooves us all: the CAA, patients, researchers, everyone, to think about strategy, and how to drive BREAKTHROUGH change for our community, not just incremental improvements. And that requires - especially for the CAA - strategic insight, and CHANGE.
And again... B2B (back to bed)...